Wnt-C59 in combination with temozolomide (TMZ) inhibits tumor formation and improves mice survival in vivo. (IMAGE)
Caption
(A) Representative hematoxylin-eosin staining of brains from mice four weeks post tumor implantation. U87MG and GSC11 cells were implanted into the right frontal lobes of nude mice (5 × 105 cells/mouse). TMZ was injected intraperitoneally at a dose of 82.5 mg/kg/d for 7 days, Wnt-C59 treatment was given daily by oral gavage (10 mg/kg/d) for 14 days. Wnt-C59 and TMZ suppressed tumor growth and reduced tumor diameter. Tumor diameters were quantified in hematoxylin-eosin-stained coronal sections by measuring tumor diameters at the largest cross-sectional area. The data were mean ± standard deviation. *P < 0.05 and **P < 0.01. (B) Survival analysis of mice intracranially implanted with GSC11 and U87MG cells. Athymic mice were intracranially implanted with GSC11 or U87MG cells (5 × 105 cells/mouse). Two weeks post-injection, mice were divided into four treatment groups (10 mice per group): i) control, oral saline for 14 days; ii) Wnt-C59, oral gavage (10 mg/kg/d) for 14 days; iii) TMZ, 82.5 mg/kg/d for 7 days; iv) combination of Wnt-C59 and TMZ. Combination therapy significantly increased the survival of GSC11- and U87MG-bearing animals compared with the control group and monotherapy groups. ***P < 0.001.
Credit
Xiaowei Zhang, Zhongyong Wang, Taohui Ouyang, Brayden Wang, Richard I. Joh, Suyun Huang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND